Clinical Trial

Washed Microbiota Transplantation for the Treatment of Oncotherapy-Related Intestinal Complications

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 6, 2025 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
Gut microbiota, known as "unrecognized organs", is closely related to the occurrence and development of tumors. Cancer is thought to occur secondary to local chronic inflammation. And some bacteria, such as Helicobacter pylori, also have direct genotoxicity, changing intracellular signaling pathways and thus causing abnormal cell growth. Systemic intestinal dysbiosis may lead to cancer, and fecal microbiota transplantation (FMT) can be a new weapon in anti-cancer treatment.Washed microbiota transplantation (WMT), a new stage of FMT, is based on the automatic microfiltration machine (GenFMTer, Nanjing, China) and the following repeated centrifugation plus suspension with support from specific facilities. The investigators conducted a prospective, one-arm, open-label study on the efficacy and safety of WMT in the treatment of oncotherapy-related complications. This study aimed to exploring the therapeutic potential of WMT in the treatment of oncotherapy-related intestinal complications and improving the quality of life of patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-01-20; most recent amendment 2025-03-03.
Trial Details
NCT Number NCT04721041
Lead Sponsor The Second Hospital of Nanjing Medical University
Conditions Intestinal Complications, Cancer
Enrollment 200 participants
Start Date 2021-01-26
Primary Completion 2025-05 (estimated)
Study Completion 2025-05 (estimated)
Updated on ClinicalTrials.gov 2025-03-06